NCT05013554 - Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions

Neoplasm MalignantBreast CancerLung Neoplasm MalignantGastric CancerNeoplasm

Interventions

DRUG

SAR443216 IV

Pharmaceutical form: Powder for solution; Route of administration: IV infusion

DRUG

SAR443216 SC

Pharmaceutical form: Powder for solution; Route of administration: SC injection

Trial Locations (11)

Investigational Site Number : 1580001, Taichung

Investigational Site Number : 1580002, Tainan City

Investigational Site Number : 0560002, Ghent

Investigational Site Number : 7240001, Madrid

Investigational Site Number : 7240002, Madrid / Madrid

Investigational Site Number : 2500001, Pierre-Bénite

~University of Texas - MD Anderson Cancer Center Site Number : 8400002, Houston

Investigational Site Number : 2500002, Villejuif

Investigational Site Number : 4100001, Seoul

Investigational Site Number : 4100002, Seoul

Investigational Site Number : 7240003, Barcelona